At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 120 enrolled
Drug / intervention
Metadoxine (MG01CI)drug
Likely dose
Metadoxine (MG01CI) 1400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-blind, Placebo-controlled, Multi-center Study Designed to Evaluate the Efficacy, Safety and Tolerability of Metadoxine Extended Release in Adults With Attention Deficit Hyperactive Disorder
In Brief
A Phase 2 clinical trial evaluating Metadoxine (MG01CI) for ADHD. Completed, enrolled 120 participants across 2 sites.
Detailed Summary
The purpose of this study is to evaluate efficacy, safety and tolerability of metadoxine (MG01CI) extended release formulation for the treatment of adults diagnosed with ADHD
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsADHD
CountriesIsrael
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2010
Enrollment StartFeb 2011
Primary CompletionAug 2011
Study CompletionSep 2011
TodayJul 2026
First PostedNov 18, 2010
Enrollment StartFeb 1, 2011
Primary CompletionAug 1, 2011
Study CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 15.6 years ago
Interventions
Metadoxine (MG01CI)drug
MG01CI 1400 mg, that will be taken daily by the patients for a duration of 6 weeks.